Human papillomaviruses (HPVs) are recognized as important human pathogens, causing a spectrum of hyperproliferative lesions from benign warts to cervical dysplasias/ carcinomas. HPV-associated lesions require continued production of the oncogenic E6/E7 proteins, which are encoded by either bicistronic or overlapping mRNAs. Here we targeted the E6/E7 mRNA of HPV11, a type implicated in causation of genital warts, using molecular reagents. Accessible sites in the HPV11 E6/E7 RNA were identified using library selection protocols, and nucleic acids (DNAzymes, antisense oligonucleotides) targeted to these sites were constructed, and tested in cell culture and on human foreskin grafts. While DNAzymes were at least equally effective in cell culture, antisense oligonucleotides targeted to the region surrounding one of the library-selected sites (ASO 407 ) proved most effective in blocking progression of HPV11-induced papillomas in human foreskin grafts on immunodeficient mice. In total, 11 papillomas were treated with ASO 407 . Of these, four of seven small papillomas treated with ASO 407 showed loss of detectable virus by in situ hybridization (ISH), and in all four of these, papillomas were no longer evident grossly or histologically after treatment. When larger papillomas were treated, one of four showed loss of virus by ISH, associated with a minor decrease in papilloma size. Considering all 11 papillomas treated with ASO 407 , loss of viral staining by ISH was significantly different from that observed in controls (Po0.016), as was true for the seven small treated papillomas (Po0.012). DNAzymes targeted to the same site (or other library selected sites) did not produce statistically significant differences in ISH staining (Po0.15). Our results with ASO 407 appear to represent the first specific molecular therapy against a bona fide HPV infection, and provide a rational proof-of-principle strategy for development of molecular therapeutics targeting other HPV-associated lesions.
Introduction
Human papillomaviruses (HPVs), members of the papillomavirinea family of viruses, are recognized as an important human pathogen. Various types of HPVs are tropic for cutaneous and mucosal epithelial cells, and consequently they are involved in development of papillomas (including common, genital, and planter warts), and more importantly cervical carcinomas. 1 A relatively limited number of HPV types are involved in nearly 100% of all carcinomas of the cervix, 2 with 16 and 18 clearly constituting 'high-risk' types. In HPV-associated cervical carcinomas, viral integration generally occurs and proteins from the E6/E7 bicistronic mRNAs (which are characteristic of oncogenic HPV types) are universally expressed; 3, 4 in fact, their expression is derepressed following integration of HPV DNA. 3, 5, 6 Expression of E6 and E7 proteins causes cell cycle deregulation by interfering with pRb and p53, respectively. [7] [8] [9] The importance of expression of these proteins in cervical carcinogenesis is highlighted by the fact that cervical carcinomas without apparent HPV involvement consistently show 'compensatory' mutations in p53 5 (however, see Walboomers et al for controversy about the existence of HPV-negative, lesions). In addition, immortalization of human epithelial cell cultures can be achieved using HPV subgenomic fragments expressing E6 and E7. 13, 14 E6/E7 expression is also necessary to support the uncontrolled proliferation of epidermal cells in papilloma development (where viral integration does not occur), for example, in the cottontail rabbit papillomavirus model. 15, 16 In human genital warts associated with HPV11, the E6 and E7 proteins are encoded on distinct RNAs which overlap. 17 With these features in mind, E6/E7 transcripts should constitute a unique target for molecular reagents against HPV. Indeed an extensive literature has accumulated describing the use of antisense oligonucleotides (ASO) and ribozymes (Rz) targeted to HPV E6/E7. [18] [19] [20] [21] [22] [23] [24] [25] However, rather than constituting a panacea for anti-HPV therapies, many view the E6/E7 targets more as beckoning Sirens. In general, successful attacks on E6/E7 have been restricted to the world of cell culture, where CaSki and/or SiHa cells (human cervical carcinoma cell lines, which contain integrated HPV16 and which at least partially require E6/E7 expression) have been inhibited in their growth, sometimes specifically, other times nonspecifically. In a few cases, CaSki or SiHa cells transfected with HPV16 E6/ E7 -targeted reagents have also shown diminished tumorigenicity in nude mice. 19, 22 Unfortunately, there have been no effective and specific molecular treatments reported for bona fide HPV infections, or for related papillomavirus infections (for example, with the cottontail rabbit model), although in one case antisense molecules targeted to HPV11 E1 mRNA showed nonspecific antiviral activity. 26 The reason for the rather limited success in targeting E6/E7 probably lies in the nature of the target per se. Venturini et al 27 have described the 'low accessibility' of most sites on HPV16 E6/E7 RNA, using a kinetic binding approach. To overcome this inherent difficulty, we developed library selection protocols 28, 29 and used them to identify accessible sites in E6/E7 target RNA from HPV11 (implicated in causation of genital warts) and HPV16 (implicated in cervical cancer). Ribozymes targeted to library selected sites in the E6/E7 targets were initially constructed, and proved very effective in cell culture against both HPV16 E6/E7 29 and HPV11 E6/E7 . 30 However, topical delivery of expression constructs was poor when tested with a variety of delivery vehicles, including cationic liposomes, 31 and so here we concentrated on smaller oligonucleotides. Sites identified in HPV11 E6/E7 were targeted with ASO and/or DNAzymes (Dz), tested in cell culture, and used to topically treat HPV11-infected human foreskin grafted onto immunodeficient mice. In spite of the anticipated advantages with catalytically active Dz, the reagent showing the greatest efficacy in vivo was an ASO targeted to a site which had been identified in two different library selection protocols.
Results
A full-length transcript of HPV11 E6/E7 RNA (see Materials and methods) was produced in vitro and subjected to library selection using a random pool of oligonucleotides (LS1) or a pool of active ribozymes (LS2) with random flanking sequences. A number of sites were identified with each protocol. Dz were constructed, which were targeted to these sites and tested in vitro for activity against the E6/E7 target. Three representative Dz (Dz 27 , Dz 338 , and Dz 407 , identified with the LS1 protocol and designated according to cut site) were selected for further testing (Figure 1 ). The cut sites were chosen within the accessible regions according to Dz specificity considerations (ie, an R-Y doublet for Dz). Dz targeted to the identified sites showed a spectrum of activities: for example, Dz 27 showed no catalytic activity, Dz 338 showed some activity, and Dz 407 showed good activity ( Figure  1a ). Of note was the fact that the 407 site was identified using both LS1 and LS2 protocols. In fact, out of 12 sites identified with the LS2 protocol, Dz 407 was the only Dz showing good activity. Inactivity of Dz targeted to sites identified using the ribozyme LS2 protocol has been a routine finding; the underlying basis is unclear.
For cell culture studies, 293T Flp-In cells were first transfected with an HPV11 E6/E7 construct, and stably transfected cell lines (293T E6/E7 ) expressing the integrated single copy of the E6/E7 DNA were obtained by antibiotic selection. These 293T E6/E7 cells expressed HPV11 E6/E7 mRNA at levels roughly 6 Â greater than the corresponding expression levels for HPV16 E6/E7 mRNA in CaSki cells, as determined using QPCR (C T values were 24.370.2 versus 27.070.6, respectively). The 293T E6/E7 cells were then transfected with the Dz ASO inhibition of HPV11 papilloma progression GA Clawson et al targeted to library-selected sites, and cellular RNA was isolated at 1, 2, and 3 days following transfection. After 1 day, all of the constructs showed substantial reductions in HPV11 E6/E7 target ( Figure 1b ). Effects were similar at day 2, with all Dz constructs producing 50-60% reductions in target RNA (given a 70-90% transfection efficiency, this corresponds to a 60-75% reduction in target in transfected cells). Effects were generally diminishing (but still evident) by day 3. A catalytically inactive mutant of Dz 407 (Dz 407m ) produced effects which were equivalent (on day 3, even superior) to those of Dz 407 . Dz 27 (which is devoid of catalytic activity) produced major reductions in target RNA at all the three time points, clearly indicating that the activities observed under these conditions were attributable to antisense effects, so further in vivo testing also included ASO directed to these sites. Given these results (and in vivo results to be described), we also tested ASO 407 in cell culture using the 293T E6/E7 cells. Highly significant reductions were observed with both ASO 407 and ASO 407 p as compared with an irrelevant ASO AR2000 p (Figure 1c ). The reductions appeared smaller in this set of experiments due to a lower transfection efficiency; if a 50% efficiency is assumed, the reductions (particularly at day 3) were comparable to those with Dz or catalytically inactive Dz (Figure 1b) .
In vivo delivery of ASO/Dz to mouse skin and human xenografts
In preliminary experiments, topical delivery of expression constructs was quite poor, when tested with a variety of delivery vehicles, including cationic liposomes 31 (data not shown). We therefore concentrated on delivery of smaller oligonucleotides (ASO and Dz). In initial studies, delivery of fluorescein-labeled ASO to full-thickness xenograft human epidermis and mouse epidermis was excellent using 1 or 2 mg/ml DNA in a 70:30 mixture (v:v) of lipofectamine:ethanol ( Figure 2 ). Delivery of fluorescein-labeled Dz was generally similar, although somewhat more variable under the same conditions ( Figure 2 ).
Effects of ASO and Dz on papillomas in human xenografts
For in vivo studies, we utilized a model wherein human foreskin, obtained locally from a consortium of hospitals/physicians, was infected with HPV11 viral stock, 32 and grafted onto NIH-III triple immunodeficient mice. In this model, papillomas develop and become visible grossly after a characteristic incubation period. For these experiments, this period was 3878 days (although this was longer in two experiments which utilized a different HPV11 stock with lower viral DNA content). Topical application of various ASO or Dz was begun at the time papillomas became evident macroscopically. The overall average papilloma area for all specimens at the time treatments commenced was 16714 mm 2 . In two experiments, four papillomas were allowed to grow to greater size (78720 mm 2 ) prior to commencement of treatment. Treatment was continued every other day on a Monday/ Wednesday/Friday schedule for 4 weeks, at which time the experiments were terminated and the grafts were processed for histology and ISH. In total, 21 foreskin grafts were treated with either Dz (as indicated, n ¼ 10 grafts) or ASO 407 (n ¼ 11 grafts), excluding various controls. Controls (n ¼ 11 grafts) included grafts treated with an irrelevant Dz (Dz AR2000 ), irrelevant ASO (four received ASO AR2000 p), PBS, or vehicle alone.
The largest and most consistent therapeutic responses were observed with ASO 407 , either as protected (3 0 -inverted T) or unprotected ASO (see Tables 1 and 2 , and Figure 3 ). Seven small papillomas were treated with ASO 407 . Where available, the average area for these small papillomas at the time treatments were started was 16712 mm 2 (Table 2) , compared with the control average of 1075 mm 2 (the difference was not significant, with P ¼ 0.21). In four of these seven grafts, an apparent therapeutic success was achieved: no residual papillomas remained grossly or histologically, and no residual HPV11 could be detected in the grafts by ISH (Tables 1  and 2 , and Figure 3 ; note the complete lack of hybridization in panels A2, B2, and C2).
Four papillomas were allowed to grow significantly (78720 mm 2 ) before treatment with ASO 407 was commenced (113 days following infection/grafting). In one of these large papillomas treated with ASO 407 , no residual HPV11 was detected by ISH (Tables 1 and 2) , although gross and histologic evidence of the papilloma remained at the end of treatment. This papilloma had a slight reduction in size in contrast to grafts with persistent virus (Table 2 ). In the other three large papillomas, some histologic evidence suggestive of antiviral effects was observed (see below). The negative ISH rate for small papillomas (four of seven) differed significantly from the rate observed in concurrent (Po0.025) and historical (see Christensen et al [33] [34] [35] [36] ) controls using Fisher's exact probability test (Po0.012). For all papillomas (large and small) treated with ASO 407 , the negative ISH rate (five of 11) also differed significantly from the control rate (Po0.016). In addition to the complete responses (ie, Figure 1 (a) Catalytic activity of Dz targeted to library-selected sites. Dz were constructed and tested in vitro as described, using 32 P-labeled HPV11 E6/E7 . Reactions were conducted as described, for 0.5 or 2 h at 371C. Dz 407 showed very good activity. In contrast, Dz 27 showed no activity, and Dz 338 showed only poor activity. Dz targeted to sites identified with the LS1 protocol have shown variable activity versus target RNAs, while Dz targeted to sites identified with the LS2 protocol have routinely shown little or no catalytic activity versus target. 39 (b) Efficacy of Dz in cell culture. 293T E6/E7 cells, stably expressing an integrated copy of HPV11 E6/E7 at relatively high levels, were transfected with Dz targeted to the libraryselected sites. Cellular RNA was isolated at 1, 2, and 3 days after transfection with Lipofectamine, and analyzed using QPCR. Dz effects were maximal at 1-2 days, but were still evident at day 3. Transfection efficiency was estimated to be 70-90% in this series of experiments. As a control, cells were also transfected with an irrelevant Dz AR2000 . Under these conditions, Dz 407m produced effects equivalent to those of Dz 407 , and in fact showed superior results at day 3. Dz 27 , which showed no catalytic activity in vitro, also produced major reductions in E6/E7 target at all time points. Reductions in target RNA were clearly not related to catalytic activity. (c) Efficacy of ASO in cell culture. 293T E6/E7 cells were transfected with ASO 407 , ASO 407 p, or an irrelevant ASO AR2000 p using Oligofectamine. Transfection efficiency was lower in this series of experiments (perhaps 50%). Cellular RNA was isolated at 2 and 3 days following transfection and analyzed using QPCR. ASO 407 and ASO 407 p produced equivalent, highly significant reductions in target RNA at both time points. ASO 425 p, which is targeted to the homologous site in HPV16 E6/E7 and contains mismatches for the HPV11 E6/E7 target, produced a minor inhibition, as compared to the irrelevant ASO AR2000 p control (not shown). P-ATP, and incubated in cell culture medium for 0-48 h, after which the ASO were purified from the medium and analyzed by PAGE and autoradiography. Addition of the 3 0 -inverted T residue resulted in essentially complete protection of ASO P , whereas about 80% of unprotected ASO was degraded over the same period. Panels B1 and B2: Topical delivery of fluoresceinlabeled ASO in mouse skin. A representative ASO was labeled with fluorescein and applied topically to triple-immunodeficient mouse skin at 2 mg/ml in lipofectamine:ethanol (70:30). After 24 h, skin was harvested, and frozen sections were examined for fluorescence (panel B1). The section was then fixed and stained with H&E (panel B2). As is evident, delivery was excellent to full-thickness epidermis, and to appendages such as hair follicles. Bar indicates 100 mm. Panels C1 and C2: Topical delivery of fluorescein-labeled Dz in mouse skin. A representative Dz was labeled with fluorescein and applied topically to mouse skin as described (panel B). After 24 h, the skin was harvested and frozen sections were examined for fluorescence (panel C1). The section was then fixed and stained with H & E (panel C2). Penetration of the labeled Dz was noted in epidermis, hair follicles, and sebaceous glands. Bar indicates 100 mm. Panels D1 and D2: Topical delivery of fluorescein-labeled ASO in human skin. Grafts of neonatal foreskin were infected with HPV11, and after small papillomas developed they were treated as described (panel B) and examined 24 h following topical application. The section was examined for fluorescence (panel D1), and then fixed and stained with H & E (panel D2). Epidermal penetration of the ASO was similar to that observed with mouse skin. Bar indicates 100 mm.
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GA Clawson et al no visible lesion and negative ISH), potential partial responses were also observed histologically in the remaining six of 11 ASO 407 -treated grafts, consisting of localized reductions in ISH signal ( Figure 4) . These, however, were not accompanied by reductions in the size of the papillomas. Treatment effects (particularly ISH staining effects) in partial responders appeared to be inversely related to the extent of hyper-and parakeratosis within local regions within the papillomas ( Figure  4 ). There was no clear enhancement of activity with the protected ASO 407 p versus ASO 407 , despite the significant increase in stability observed in vitro with the former (see Discussion). The focal loss of ISH staining in areas associated with attenuated keratin appeared to be more prominent than in controls treated with irrelevant ASO AR2000 or Dz AR2000 .
In the Dz-treated grafts, three of 10 were negative for HPV11 DNA using ISH (Table 1 and Figure 5 , panels A2 and B2), a result which did not differ significantly from the control rate (Po0.147). A negative ISH result was obtained with Dz 407 , Dz 407m , and Dz 338 . In each of these cases, however, residual papillomas were observed grossly and histologically following treatment, and reductions in gross papilloma size were not noted. Apoptotic nuclear debris was often evident ( Figure 5 , panel A3); this response was particularly prominent in samples treated with Dz 407 , and again may reflect partial penetration/uptake of Dz, even in areas with relatively little keratinization. This cellular response was often accompanied by a notable loss of koilocytes. In seven of 10 grafts demonstrating positive ISH, potential therapeutic effects (for example, apoptotic debris) were variably observed microscopically, but were restricted to the upper layers of the epidermis.
Discussion
Despite an increase in our understanding of the relationship between HPV and cancer, few advances have been made in the treatment of HPV-associated lesions, including genital and common papillomas. Most therapeutic modalities are aimed at achieving tissue destruction and they demonstrate tremendous variability in their rate of response and duration of effect. Such treatments include cryotherapy, cautery, laser therapy, acids, podophyllin, and intralesional chemotherapeutic agents. Recently, alternative approaches have emerged utilizing topical biological response modifiers such as imiquimod, which bolsters cellular immune responses directed against virally infected keratinocytes and also exhibits antitumor effects. 37 In all, 19 of 51 patients (37%) who were treated topically with 5% imiquimod three times a week for 8 weeks achieved complete clearing compared with 0 of 57 (0%) of placebo-treated patients. 37 The goal of the present study was to design and test reagents targeted to the E6/E7 mRNA of HPV11, as an alternative means of suppressing papilloma progression. Library selection protocols were developed and used to identify accessible sites in an HPV target mRNA, whose expression has been shown to be critical in the development of HPV-associated lesions, namely the overlapping E6/E7 mRNAs. Both the LS1 selection protocol 28 and the LS2 protocol 29 employed iterative binding steps to enrich the libraries for accessible binding regions. LS1 employs a library of random oligonucleotides and identifies sites accessible for binding, whereas LS2 employs a library of random Rz and directly identifies Rz cleavage sites.
The 407/409 cut site region in the HPV11 E6/E7 RNA was identified in both LS1 and LS2 protocols, and this warrants some comment. This region is homologous to the 427-nt region in HPV16 E6/E7 mRNA, one of the HPV types important in cervical cancer. In HPV16 E6/E7 mRNA, sites/regions 434 19 or 437-447 27 were previously described by others. Since different numbering schemes were used, the 434 site identified by others 19 corresponds to our 338 site (as a hammerhead ribozyme, Rz 338 would cleave after 436 nt in the alternate numbering scheme). Rz 338 was in fact identified in an HPV16 E6/E7 LS1 protocol we performed. 29 In our hands, however, Rz 338 activity was slightly lesser than that of Rz 427 in vitro, and Rz 427 showed superior effects in cell culture (the 427 site in HPV16 E6/E7 would correspond to 506 nt in GenBank Accession #K02718).
Although we had previously identified Rz which were very effective versus HPV16 E6/E7 and HPV11 E6/E7 , 29, 30 when we began topical delivery studies we found that delivery/expression was very poor for any of the reporter plasmid constructs we tested, effectively eliminating deployment of the targeted Rz constructs. Therefore, further experiments focused upon delivery of the smaller ASO and Dz. Dz produced substantial reductions in HPV11 E6/E7 target RNA in cell culture, in spite of . Of these, four papillomas showed negative ISH signals, as well as complete regression of the papillomas. This negative ISH rate (four of seven) also differs significantly from the control rate (Po0.012). Four papillomas were larger when treatment was begun (average area 78720 mm 2 ). One of these was negative for viral DNA by ISH, but a papilloma was still evident grossly and histologically after treatment. ASO inhibition of HPV11 papilloma progression GA Clawson et al the relatively high target expression levels (and o100% transfection efficiencies). However, since catalytically inactive Dz produced equivalent results, ASO constructs targeted to the selected sites were also included in subsequent testing in vivo (and were shown to produce significant reductions in target RNA in cell culture). In addition, ASO and Dz constructs were also tested with 3 0 -inverted T's as protective groups: the 3 0 -inverted T constructs showed significantly increased stability in medium and within cells. However, the 3 0 -inverted T modification did not increase the efficiency of Dz in cell culture under the conditions utilized, and more importantly it had no demonstrable effect on the efficacy of ASO in vivo. We speculate that the doses of ASO utilized may have been 'saturating' at the arbitrary concentration tested. One would expect that enhanced activity with 3 0 -inverted T moieties might become apparent at lower doses, or with extended intervals between applications.
Papillomas in humans are known to sporadically undergo spontaneous resolution. It is thought that this phenomenon, which is uncommon, is immunologically mediated. For example, during the 8-week observation period in the studies of genital papillomas treated with imiquimod, 37 0/57 control lesions underwent spontaneous regression. With our human foreskin graft model, no control papillomas showed evidence of spontaneous regression during the observation period. Furthermore, since spontaneous regression of papillomas is immunologically mediated, this phenomenon would not be expected to occur in immunodeficient mice.
Grafts treated with ASO 407 showed the greatest therapeutic efficacy, eliminating viral DNA ISH signal in five of 11 samples. In fact, of the seven small papillomas (average areas of 16712 mm 2 ) treated with ASO 407 , four showed complete gross/histologic regression and were negative by ISH. As stated, this negative ISH rate is significantly different from the control rate. If this can be regarded as a complete response (cure) rate, this rate is comparable or even superior to that achieved with topical imiquimod 37 and other therapies. When substantially larger papillomas were treated, one of four was negative by ISH, but in that case the papilloma remained evident grossly and histologically. These data Figure 3 Effects of topical application of HPV11 E6/E7 -targeted ASO 407 on papilloma progression in human foreskin grafts. Grafts were treated with 25 ml of a 1 mg DNA/ml solution every other day for 20 days. Rows A and B show separate human foreskin grafts following treatment with ASO 407 (unprotected). Row C shows a graft after treatment with protected ASO 407 p (containing an inverted T at the 3 0 -end). Row D shows a control graft treated with an irrelevant ASO. Column 1 shows low power (4 Â ) H & E-stained photomicrographs, column 2 shows the corresponding ISH results, and column 3 shows higher power H & E-stained photomicrographs of the same grafts. In the grafts shown after treatment with ASO 407 /ASO 407 p, no residual papillomas were observed histologically (panels A1, B1, and C1). In addition, note the complete lack of ISH signal for viral DNA evident after treatment of three different grafts with ASO 407 (panels A2, B2, and C2), compared with a control graft treated with an irrelevant ASO (panel D2, arrow). Negative ISH results were observed in two additional grafts treated with ASO 407 , one small papilloma and one large papilloma (not shown).
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GA Clawson et al suggest that ASO 407 may be most useful clinically for treatment of early lesions. Dz 407 (and other less active Dz targeted to other library selected sites) also showed effects suggestive of some therapeutic efficacy, at least microscopically, in terms of loss of viral staining and cellular effects. In three of 10 grafts, ISH for viral DNA was negative, although here again gross/histologic evidence of the papilloma remained at the end of therapy. One possibility is that there may be a lag time between viral eradication and regression of the papilloma, but this hypothesis was not addressed in these experiments.
The therapeutic effects of Dz in vivo appeared to be restricted to the upper levels of the epidermis, where apoptotic nuclear debris was often observed, as was an absence of koilocytosis. This effect was greatest with Dz 407 , and appeared to be specific, since it was not observed after treatment with irrelevant Dz. Restriction to the upper levels of epidermis might reflect poorer penetration of Dz versus ASO (32 versus 17 nt, respectively), although this was not clearly supported in topical delivery studies with fluorescein-labeled oligonucleotides, or it might reflect lower cellular uptake of the Dz.
The partial potential responses observed with ASO 407 or Dz clearly correlated with the local thickness of the keratin layer. ISH for HPV11 DNA showed strong staining in areas showing extensive keratinization in residual lesions, and often showed little/no residual staining in areas with little keratinization. While this relationship might be expected given the relationship between viral amplification and keratinocyte differentiation, we also speculate that the extent of keratinization may affect penetration, which could contribute to the reduced efficacy in areas of extensive hyperkeratosis. In Figure 4 Heterogeneous effects of topical application of HPV11 E6/E7 -targeted ASO 407 and Dz 407 on papilloma progression in human foreskin grafts. Grafts were treated on a Monday/Wednesday/Friday schedule with 25 ml (1 mg DNA/ml) of the various ASO or Dz, and after 4 weeks of treatments grafts were harvested and processed for histology and ISH. Panels A shows a graft treated with protected ASO 407 ASO inhibition of HPV11 papilloma progression GA Clawson et al that case, improved results would be expected in early papillomas which are less extensively keratinized, and/ or when topical application of ASO 407 is combined with a pretreatment aimed at reducing the thickness of the stratum corneum, such as topical salicylic acid, paring, or cryotherapy. This may not represent an obstacle when treating mucosal surfaces.
Materials and methods

Library selection of target sites
The HPV11 E6/E7 RNA used in these selection protocols consisted of the coding regions for the overlapping E6 and E7 mRNAs. The region used represented 102-826 nt from GenBank Accession #M14119. Nucleotides 102-554 constitute the coding region for E6, while 530-826 nt constitute the coding region for E7. Library selection was performed using two protocols. In the first (LS1), a random oligonucleotide library SELEX procedure was performed (five rounds) according to Pan et al. 28 In the second (LS2), library selection was performed using a random library of active Rz. 29 Briefly, the library was allowed to bind to HPV11 E6/E7 target RNA under inactive conditions, and the bound species were reamplified, and a second round of binding/amplification was performed at a lower target:Rz ratio to increase the specificity. The selected pool was then transcribed into active Rz and incubated with full-length 5 0 -32 P-HPV11 E6/ E7 -labeled target RNA. Cleavage products were separated on sequencing gels, and sites of cleavage were then directly identified by comparison with G-, T-, and base hydrolysis ladders. Of note was the identification of one common site in both protocols, surrounding 407 nt. This corresponds to 505 nt in GenBank accession #M14119, and is contained in both of the overlapping HPV11 E6 and E7 RNAs.
In vitro studies
For in vitro testing, Dz were synthesized and tested under conditions as previously described. 28 The Dz (and ASO) were obtained from DNagency (Malvern, PA, USA). Where indicated, an inverted T was added to the 3 0 end. 38 This modification significantly protected ASO/ Dz against degradation in medium/serum and in cells 338 , and PBS negative control (respectively). In all, 25 ml (1 mg DNA/ml) solution was applied every other day for 30 days. Negative ISH results are noted with Dz 407 (A2) and Dz 407m (B2). In contrast, treatment with Dz 338 and PBS resulted in persistence of viral mRNA (panels C2, D2, arrows). In each of these samples, gross evidence of papilloma was present (Column 1); however, with Dz 407 (panel A3) apoptotic nuclear debris is present (arrow). Bars denote 250 or 100 mm as indicated.
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GA Clawson et al (see below). Over the course of these experiments, multiple different batches of Dz and ASO were synthesized, and all were purified by high-pressure liquid chromatography, aliquoted, numbered sequentially according to order number, bar-coded, and stored at À701C under GLP-like conditions. The sites targeted were those identified using the LS1 protocol, since Dz targeted to sites identified with the LS2 protocol routinely show poor/no activity. 39 The various Dz and ASO constructs were: P-labeled ASO P and unprotected ASO were then incubated for various periods in medium (DMEM710% heat-inactivated bovine calf serum), or they were transfected into 293T cells, and RNA was isolated 1, 3, and 5 days following transfection. No degradation of protected ASO P was observed after 48 h of incubation in medium7serum, compared with 70-80% degradation for the unprotected ASO (see Results, Figure 2a ). After transfection into 293T cells, ASO P also showed substantially greater stability (data not shown).
293T cells were stably transfected using the Flp-In system (Invitrogen). Flp-In 293T cells were grown in the presence of zeocin (400 mg/ml) to maintain the FRT site (used for targeted recombination at a unique site in the genome). The HPV11 E6/E7 sequence was cloned into the pcDNA5 vector: As stated, the region used represented 102-826 nt from GenBank #M14119. Nucleotides 102-554 represent the coding region for E6, while 530-826 nt represent the coding region for E7. This construct, which is under the control of the CMV promoter, was then cotransfected into the Flp-In 293 cells along with p0G44 (the vector allowing expression of the Flp recombinase) using Lipofectamine PLUS reagent. At 2 days after transfection, antibiotic selection with hygromycin B (30 mg/ml) was begun, which selected for the integrated pcDNA5/FRT construct. After 30 days, single colonies were picked, tested for b-galactosidase activity, and subsequently for HPV11 E6/E7 expression; the stably transfected cells were designated 293T E6/E7 . For comparative purposes, expression of HPV11 E6/E7 was about 6 Â greater than that of HPV16 E6/E7 in CaSki cells (see Results).
The 293T E6/E7 cells were subsequently transfected with the various Dz or ASO constructs targeted to the HPV11 E6/E7. Transfection efficiency was estimated to be 70-90% in initial experiments using Dz and Lipofectamine PLUS. In later experiments with ASO, Oligofectamine (InVitrogen) was used, and the transfection efficiency was lower (perhaps 50%), as was estimated based upon use of fluorescently labeled ASO.
HPV11 E6/E7 target RNA levels were quantitated using real-time PCR (QPCR). We used a Stratagene (La Jolla, CA, USA) M Â 4000 machine and TaqMan 5 0 -nuclease methodology, with either VIC or 6-carboxy-fluorescein (FAM) and Black Hole Quencher 1 (BHQ). For amplification of HPV11 E6/E7 , the initial 3 0 -primer used was reverse complementary to 827-803 nt. For QPCR, the 3 0 -primer was reverse complementary to 226-203 nt, and the 5 0 -primer matched 154-175 nt. The TaqMan probe was (FAM)-CTT TCC CTT TGC AGC GTG TGC CTGT-(BHQ), which matched 177-201 nt. mRNA for the ubiquitous transcription factor TATAbox binding protein (TBP, an integral component of TFIID) was used for normalization. 40 For amplification of TBP, the initial 3 0 -primer was CTG GAA AAC CCA ACT TCT GTA CAA, which was reverse complementary to 742-718 nt. For QPCR, the same 3 0 -primer was used. The 5 0 -primer was ACC ACG GCA CTG ATT TTC AGT, which matched 625-646 nt. The TaqMan probe was (VIC)-TGT GCA CAG GAG CCA AGA GTG AAGA (BHQ), which matched 659-683 nt. ROX (carboxy-Xrhodamine, succinimidyl ester) was used as dye for a volume control. In some experiments, 18S ribosomal RNA was also quantitated. 29 RT reactions utilized Sensiscript reverse transcriptase (Qiagen) with 50 ng RNA; standard curves were generally run with 25-100 ng total RNA. QPCR reactions used HotStar Taq Polymerase (Qiagen). In all, 2 ml of the RT reaction was used in a 20 ml reaction. Amplifications were performed in triplicate, and HPV11 E6/E7 and TBP were matched from the same RT reactions for each. Initial denaturing was at 951C for 15 min; cycles consisted of 951C for 30 s, 561C for 1 min, and 721C for 30 s.
Data were analyzed using the REST program, using the pair-wise fixed reallocation randomization test, 41 using TBP as reference (results were similar without normalization).
In vivo delivery of ASO/Dz to mouse skin and human xenografts
In initial studies, fluorescein-labeled ASO or Dz were prepared in lipofectamine:ethanol (70:30, v:v) at concentrations of 1 or 2 mg/ml. This delivery vehicle was tested based on earlier results by Lieb and co-workers, 42 which documented the effective delivery to hair follicles. ASO or Dz in lipofectamine:ethanol was applied topi-cally to human foreskin or breast skin grafts, or to the back skin of 5-10-week-old female NIH-III triple-deficient mice (#NIHBNX-MMC, Harlan Laboratories, Indianapolis, IN, USA). These mice carry three separate mutations (bg, nu, and xid), which result in deficiencies in T, B, and NK cells. Delivery was assessed by fluorescence microscopy at 6, 12, or 24 h following topical application.
Preparation of foreskin, orthotopic grafting, and treatment with ASO/Dz Foreskin fragments were prepared from circumcisions as previously described. 8 The foreskin was free of detectable lesions, and was cut split-thickness (0.5 mm), and then cut into fragments of approximately 10 Â 10 mm 2 . These fragments were incubated with 0.2 ml of HPV11 virus stock 32 for 1 h at 371C (obtained under the auspices of the NIH contract), and then grafted immediately onto 5-10-week-old female immunodeficient NIH-III mice. Small groups of mice (generally 4-6) were grafted at a time, and these studies encompass 8-10 groups over a period of about 2.5 years. In general, a foreskin specimen would yield about two grafts, and the small groups of animals included grafts from multiple specimens. The mice were anesthetized and a section of skin matching the graft size was removed over the rib cage. The graft was then placed in the area and covered with a 1 Â 1 cm 2 nonadherent dressing, which in turn was covered with porous tape wrapped around the mouse. The grafts were then allowed to heal for 10-14 days before the bandages were removed. The 'take' rate was about 60%. Visible papillomas developed 3878 days following grafting in most experiments (the period was approximately twice as long in one group infected with another HPV11 viral stock, which contained a lower concentration of virus). After infection and grafting of foreskin, topical application of the various ASO or Dz was begun at the time papillomas became established macroscopically (ie, an average area of 16 mm 2 ; see Results), thus ensuring that characteristic lesions had developed in each case (overall, papillomas developed in about 30% of the total number of grafts performed). Spontaneous regression is not observed in this model. Mice were randomly assigned to the various reagent groups on a rolling basis as they became available.
For treatment of grafts, ASO/Dz were applied topically to developing papillomas in a volume sufficient to cover its surface (25 ml, with DNA at 1 mg/ml in lipofectamine:ethanol, 70:30 v:v). Reagents were coded with oligonucleotide order numbers, and the technician evaluator was not aware of their identities. Treatment was continued every other day on a Monday/Wednesday/Friday schedule for 4 weeks, at which time the experiments were terminated and the grafts were processed for histology and in situ hybridization for detection of HPV11 DNA. Controls included papillomas which were treated with PBS, lipofectamine:ethanol vehicle, or with an irrelevant Dz AR2000 or ASO AR2000 in lipofectamine:ethanol.
In situ hybridization (ISH)
For in situ detection of HPV11 DNA, cloned HPV11 (8 kbp, Hershey strain) was labeled with Bio-11-dUTP by random priming (Megaprime DNA Labeling System, Amersham, Piscataway, NJ, USA), according to the manufacturer's instructions. Probes were diluted to 1 mg/ml in a 50% formamide hybridization cocktail (50% formamide in 2.4 M NaCl, 40 mM Tris-HCl, pH 7.4, 2 mM EDTA, 4 mg/ml BSA, 0.08% polyvinylpyrrolidone, 0.08% ficoll, 0.6 mg/ml yeast tRNA, and 80 mM dithiothreitol).
Paraffin sections were dewaxed, dehydrated with ethanol, and then digested with pepsin (4 mg/ml, in 0.1 N HCl). The tissues were then neutralized with 95% ethanol, subsequently dehydrated in 100% ethanol, and then allowed to air dry. The probe cocktail was applied and the tissue and probe were simultaneously denatured at 951C for 6 min. Hybridization was performed for 2 h at 371C in a moist chamber. The samples were then thoroughly washed in 2 Â SSC, and the hybridized probe was detected by incubation with an avidin-alkaline phosphatase conjugate, followed by colorimetric development in McGady reagent (nitroblue tetrazolium, 50 mg/ml, and 5-bromo-4-chloro-3-indoyl phosphate, p-toluidine salt, 50 mg/ml, in 50% dimethylformamide). Slides were counterstained with nuclear fast red and coverslipped in permanent mounting medium. Positive and negative controls were run with each experiment.
